Table 1.
Summary of patient background of the PD, MSA-P, PSP and control groups.
| PD (n = 311) | PSP (n = 33) | MSA-P (n = 20) | Control (n = 137) | |
|---|---|---|---|---|
| Age | 73.0* (66.0–78.0) | 74.0 (70.5–79.5) | 71.5 (65.8–75.8) | 76.0 (72.0–80.0) |
| Men, n (%) | 158 (50.8) | 18 (54.5) | 12 (60.0) | 62 (45.3) |
| Duration (y) | 2.0 (1.0–3.0) | 2.0 (1.0–2.0) | 2.0 (2.0–4.5) |
| HY stages of PD | ||||
|---|---|---|---|---|
| HY I (n = 88) | HY II (n = 106) | HY III (n = 89) | HY IV (n = 28) | |
| Age | 70.0 (63.0–76.0) | 73.0 (66.0–77.3) | 75.0 (66.5–78.5) | 77.5† (72.0–82.0) |
| Men, n (%) | 38 (43.2) | 57 (53.8) | 53 (59.6) | 10 (35.7) |
| Duration (y) | 1.0 (1.0–2.0) | 2.0 (1.0–3.0) | 3.0†† (2.0–5.0) | 4.5†† (2.0–7.5) |
Data are expressed as a median and interquartile range (IQR) or n (%).
PD Parkinson’s disease, PSP progressive supranuclear palsy, MSA-P multiple system atrophy of the parkinsonism subtype, HY Hoehn-Yahr stage.
Duration shows years of DAT-SPECT imaging from onset. *indicates P < 0.01 as compared with the control group (SPSS software, version 23.0). †indicates P < 0.01 and †† indicates P < 0.001 as compared with the PD group with HY stage I.